Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Phase II Clinical Trials of Thalidomide in NTDT
Brief Summary: This is an exploratory experiment, aims to explore the effective and safety of thalidomide in the treatment of NTDT to improve the hemoglobin level, improve the quality of life, reduce blood transfusion, so as to avoid the adverse reactions caused by transfusion.15\~30 patients will be enrolled, including type α 5\~13 cases, type β 10\~17 cases.


Options:
A: Inclusion Criteria:

1. Intermedia α-Thalassemia; intermedia β-Thalassemia; severe β-Thalassemia.
2. Syndrome of Deficiency of Liver-yin and Kidney-yin, and Asthenia of Essence and Blood.
3. Male or female, 3-40 years of age.
4. Provision of written informed consent.

Exclusion Criteria:

1. Complications with critical illness such as cerebrovascular disease, cardiovascular disease, hepatic disease, renal disease, malignancy and etc.
2. Allergy to any ingredients of Yisui Shengxue Granules
3. Psychiatric disorder.
4. Blood transfusion in the latest 90 days for severe β-Thalassemia; blood transfusion in the latest 45 days for intermediaβ-Thalassemia or intermedia α-Thalassemia.。
5. Upper respiratory tract infection with temperature higher than 38.5℃ in the latest 45 days.
6. Taking other antianemic agents in the latest 2 months.
7. Participation in any other clinical interventional trial in the latest 1 month.
B: Inclusion Criteria:

* Patients with thalassemia intermedia. Diagnosis based on genetic mutations, hemoglobin electrophoresis and characteristic clinical data at presentation.
* Require different transfusion requirements and not transfusion dependent.
* Have a baseline hemoglobin of less than or equal to 6-8g/dl.
* Patients with normal renal and liver function.

Exclusion Criteria:

* Evidence of active hepatitis (ALT \> 5 times above ULN).
* Evidence of renal impairment (serum creatinine \> ULN).
* Patients who are dependent on red blood cell transfusions.
C: Inclusion Criteria:

Patients meeting all of the following criteria will be considered for admission to the trial:

* Diagnosis of NTDT;
* Ages 18-65 years;
* ECOG: 0\~2 scores;
* Sign an informed consent agreeing to the clinical trial participation.

Exclusion Criteria:

Patients presenting with any of the following criteria will not be included in the trial:

* Patients received hydroxycarbamide, Yisui Shengxue Granule in three months;
* Women during Pregnancy, breastfeeding or those of childbearing age who do not want to take contraceptive measures;
* Patients had comorbidities like severe heart or lung diseases, liver dysfunction, cerebrovascular, cardiovascular, liver, kidney, tumor or other serious primary diseases;
* Patients Allergic to the drug ingredients;
* Patients with any Mental problem;
* Patients had Participated in other drug clinical trials in the past 1 month;
* Patients had a history of venous or arterial thrombosis;
* In certain circumstances that the researchers determined it was not suitable for the research.
D: Inclusion Criteria:

* pregnant women diagnosed as thalassemia carriers by genetic test with clinical presentation of minor or intermediate β- thalassemia;
* patients with mild anemia (80 g/L≤ Hb\<110 g/L) prior to study enrollment;
* singleton pregnancy;
* patients having not received blood transfusion or any forms of anti-anemia treatment in Western Medicine or Traditional Chinese Medicine in the last 12 weeks;
* informed consent obtained.

Exclusion Criteria:

* patients with severe thalassemia;
* patients with severe anemia (Hb\<80 g/L) prior to study enrollment;
* twin or multiple pregnancies;
* patients with any of the following abnormalities: immunodeficiency, primary diseases involving cardiovascular system, liver, kidney, gastrointestinal tract, endocrine system and hematological system;
* allergic to two or more drugs;
* patients with mental illness or poor compliance to medical treatment;
* patients having received blood transfusion or any forms of anti-anemia treatment in Western medicine or Traditional Chinese Medicine in the last 12 weeks;
* no informed consent obtained.

Answer: C